🔍

STAR - Strides Pharma

📊 NSE: STAR 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/14/2025 13:45

📢 Recent Corporate Announcements

Strides Pharma Subsidiary Completes 100% Acquisition of Neviton Softech for ₹21.77 Cr

🟢 POSITIVE ⭐ 7/10

M&A 📅 17 Feb 2026, 03:36 PM

Strides Pharma's wholly-owned subsidiary, Arco Lab, has acquired the remaining 50% stake in Neviton Softech for approximately ₹21.77 crores (Euro 2 million). Neviton, which specializes in IT services and IoT-based engineering solutions, reported a turnover of ₹27.08 crores and a PAT of ₹4.26 crores for FY25. This acquisition consolidates Neviton as a step-down subsidiary, following a phased investment strategy that began in 2022. The move is strategically aimed at enhancing Strides' internal digitization and driving operational cost efficiencies.

Acquisition of the final 50% equity interest in Neviton Softech for a cash consideration of ~₹21.77 crores.
Neviton reported a steady financial performance with FY25 turnover of ₹27.08 crores and PAT of ₹4.26 crores.
Target company specializes in high-tech areas including IoT devices and real-time data integration for engineering solutions.
Strategic integration with Arco Lab is expected to yield significant cash savings and enable better group-wide digitization.

💡 This is a strategic bolt-on acquisition that strengthens the company's internal IT and digital capabilities at a reasonable valuation. Investors should monitor how these technological synergies contribute to long-term operational margin improvements.

Strides Pharma Receives USFDA EIR for New York Facility with VAI Classification

🟢 POSITIVE ⭐ 8/10

REGULATORY 📅 05 Feb 2026, 08:49 AM

Strides Pharma's US subsidiary has received an Establishment Inspection Report (EIR) from the USFDA for its Chestnut Ridge facility in New York, marking the successful closure of the audit. The inspection, conducted in December 2025, resulted in a Voluntary Action Indicated (VAI) status following the company's response to Form 483. Significantly, the audit included a pre-approval inspection for Drug-Device Combination capabilities, specifically covering recent filings in the Nasal Sprays domain. This clearance supports the company's US growth strategy for specialized products like hormones and controlled substances.

USFDA inspection conducted from December 17 to December 23, 2025, at the Chestnut Ridge, NY facility.
Inspection outcome classified as VAI (Voluntary Action Indicated), signifying formal closure of the audit.
Included pre-approval inspection for Drug-Device Combinations, facilitating entry into the Nasal Sprays market.
The facility supports high-margin products including Liquids, Gels, Hormones, and Controlled Substances.

💡 Investors should view this as a positive regulatory milestone that de-risks the US pipeline for complex generics. Monitor for upcoming product approvals and launches in the Nasal Spray and Hormone categories from this facility.

Strides Pharma Receives USFDA EIR for New York Facility with VAI Status

🟢 POSITIVE ⭐ 8/10

REGULATORY 📅 05 Feb 2026, 08:31 AM

Strides Pharma's US subsidiary has received an Establishment Inspection Report (EIR) from the USFDA for its Chestnut Ridge facility in New York, following an inspection in December 2025. The inspection resulted in a Voluntary Action Indicated (VAI) classification, effectively closing the audit process. Notably, the inspection included a pre-approval audit for Drug-Device Combinations, specifically covering the company's recent filings in the Nasal Sprays domain. This clearance is significant as the facility manufactures complex products like liquids, gels, and hormones for the U.S. market.

USFDA inspection conducted from December 17 to December 23, 2025, at the Chestnut Ridge, NY facility.
Received Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) classification.
Inspection included pre-approval for Drug-Device Combinations for recent Nasal Spray filings.
Facility supports manufacturing of Liquids, Gels, Hormones, and Controlled Substances for the U.S. market.
Successful closure strengthens near-term growth prospects and regulatory standing in the United States.

💡 This regulatory clearance is a positive catalyst as it paves the way for new product launches in the complex Nasal Spray segment. Investors should maintain a positive outlook on the stock while monitoring the timeline for subsequent product approvals.

Strides Pharma to Attend Systematix Annual India Conference on Feb 10, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 04 Feb 2026, 09:09 PM

Strides Pharma Science Limited has announced its participation in the Manthan – Systematix Annual India Conference scheduled for February 10, 2026, in Mumbai. The management will engage with institutional investors through both group and one-on-one in-person meetings starting from 10:00 hrs. The discussions will primarily focus on the Q3 FY26 earnings presentation, which was previously released to the exchanges on January 30, 2026. This is a standard investor relations activity aimed at providing clarity on the company's recent financial performance.

Participation in Manthan – Systematix Annual India Conference on February 10, 2026
Meeting format includes in-person group and one-on-one sessions in Mumbai
Discussion will be based on the Q3 FY26 Earnings Presentation released on January 30, 2026
Event scheduled to commence from 10:00 hrs onwards

💡 No immediate action is required as this is a routine investor interaction. Investors may review the Q3 FY26 earnings presentation to understand the likely topics of discussion.

Strides Pharma Q3 FY26: Record EBITDA of ₹236 Cr; PAT Jumps 38% YoY as Margins Hit 60%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 03 Feb 2026, 04:57 PM

Strides Pharma Science Limited reported a strong Q3 FY26 performance, achieving its highest-ever quarterly EBITDA of ₹236 crores, a 12% YoY increase. While total revenue growth was modest at 3.6% due to a planned scale-down of the institutional business, operational PAT surged by 38% YoY. The company's focus on profitability led to gross margins reaching 59.8% and an EPS of ₹41.4. Notably, the Ex-US markets grew 20% YoY to $64 million, significantly narrowing the gap with the US market which remained flat at $70 million.

Highest ever quarterly EBITDA of ₹236 crores with margins expanding 160 bps YoY to 19.8%.
Operational PAT grew by 38% YoY, supported by gross margins touching the 60% mark.
Ex-US revenue increased 20% YoY to $64 million, now contributing 47% of total Q3 revenues.
Net debt reduced by ₹170 crores during the quarter, bringing the Debt/EBITDA ratio down to 1.59x.
Appointed Peter Hardwick as CEO of North American Business to lead the next growth phase beyond $400 million.

💡 Investors should take note of the significant structural improvement in profitability and the successful debt reduction trajectory. The company's reduced dependence on the US market and focus on high-margin regulated markets make it a strong candidate for long-term growth.

Strides Pharma Releases Q3 FY26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 30 Jan 2026, 08:12 PM

Strides Pharma Science Limited has officially released the audio recording of its earnings conference call held on January 30, 2026. The call focused on the company's unaudited financial performance for the third quarter and the nine-month period ending December 31, 2025. This disclosure is a routine regulatory requirement under SEBI Listing Obligations and Disclosure Requirements. Investors can access the full recording via the company's investor relations website to understand management's perspective on recent performance.

Earnings call conducted on January 30, 2026, at 16:30 hrs IST.
Covers financial results for the quarter and nine months ended December 31, 2025.
Recording made available on the company's official website under the 'Quarterly Financial Results' section.
Filing made in compliance with SEBI LODR Regulations 46 and 30.

💡 Investors should listen to the recording to gain insights into management's guidance and operational strategies for the upcoming quarters. This is particularly useful for understanding the nuances behind the Q3 FY26 financial figures.

Strides Pharma Q3FY26: Record EBITDA of ₹2,359m; Operational PAT Surges 39% YoY

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 30 Jan 2026, 12:57 PM

Strides Pharma Science Limited delivered its highest-ever quarterly EBITDA of ₹2,359 million in Q3FY26, marking a 12.2% YoY increase. While total revenue grew modestly by 3.6% to ₹11,946 million, operational PAT saw a significant jump of 38.6% YoY to ₹1,282 million. The performance was bolstered by a 280bps expansion in gross margins to 61.2% and a 20% YoY growth in Ex-US markets. Additionally, the company reduced its net debt to ₹13,527 million on a constant currency basis while funding ₹2,836 million in capex during 9MFY26.

Achieved highest ever quarterly EBITDA of ₹2,359m with margins improving to 19.8%.
Operational PAT grew 38.6% YoY to ₹1,282m, while Reported PAT hit ₹2,081m including a ₹832m property sale gain.
Ex-US markets (Australia, UK, EU) grew 20% YoY to $64m, offsetting flattish US revenue of $70m.
Net debt reduced by ₹1,694m in 9MFY26 on a constant currency basis despite ₹2,836m capex spend.
Appointed Peter Hardwick as CEO for North America to lead the target of $400m US revenue by FY28.

💡 Investors should view the record EBITDA and consistent debt reduction as strong indicators of operational efficiency. The robust growth in non-US regulated markets and the appointment of new leadership for the US business suggest a healthy outlook for achieving long-term revenue targets.

Strides Pharma Q3FY26: Highest Ever Quarterly EBITDA of ₹2,359m; Operational PAT Up 39% YoY

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 30 Jan 2026, 12:53 PM

Strides Pharma reported a robust bottom-line performance for Q3FY26, with operational PAT growing 38.6% YoY to ₹1,282m despite a modest revenue growth of 3.6% at ₹11,946m. The company achieved its highest-ever quarterly EBITDA of ₹2,359m, driven by a significant gross margin expansion of 280 bps to 61.2%. While the US business remained flattish and institutional business saw low offtake, the Ex-US regulated and growth markets performed strongly with 20% YoY growth. The company also appointed Peter Hardwick as the new CEO for its North America business to drive long-term growth.

Highest ever quarterly EBITDA of ₹2,359m, representing a 12.2% YoY growth.
Operational PAT surged 38.6% YoY to ₹1,282m with an Operational EPS of ₹13.9.
Gross margins expanded significantly by 280 bps YoY to reach 61.2%.
Ex-US market revenue grew by 20% YoY to $64m, offsetting flattish US performance.
EBITDA margins improved to 19.8%, up 160 bps compared to the previous year.

💡 Investors should take note of the significant margin expansion and profitability growth which compensates for the tepid revenue growth. Monitor the impact of the new North America CEO on the US business and the continued momentum in Ex-US regulated markets.

Strides Pharma Q3 PAT Surges 131% YoY to ₹2,081 Million; Revenue Up 3.5%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 30 Jan 2026, 12:48 PM

Strides Pharma Science Limited reported a robust performance for Q3 FY26, with consolidated Profit After Tax (PAT) more than doubling to ₹2,081.22 million from ₹900.40 million in the previous year. Revenue from operations grew steadily to ₹11,946.46 million, while Profit Before Tax (PBT) before exceptional items saw a massive jump of 115% YoY. The bottom line was significantly bolstered by a surge in 'Other Income' to ₹1,068.62 million and a 17% reduction in finance costs. For the nine-month period ended December 2025, the company has achieved a PAT of ₹4,452.39 million.

Consolidated PAT for Q3 FY26 jumped 131% YoY to ₹2,081.22 million.
Revenue from operations increased to ₹11,946.46 million compared to ₹11,536.67 million in Q3 FY25.
Profit Before Tax (PBT) before exceptional items rose to ₹2,488.05 million from ₹1,153.22 million YoY.
Finance costs decreased to ₹433.79 million from ₹521.82 million, reflecting improved debt management.
Other income saw a significant spike to ₹1,068.62 million from just ₹56.16 million in the corresponding previous quarter.

💡 Investors should take note of the significant margin expansion and debt cost reduction, though the impact of high 'Other Income' on the bottom line should be evaluated for sustainability. The stock remains a strong watch given the sharp recovery in profitability.

Strides Pharma Schedules Q3 FY26 Earnings Call for January 30, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 23 Jan 2026, 09:35 PM

Strides Pharma Science Limited has announced its earnings conference call scheduled for Friday, January 30, 2026, at 16:30 IST. The purpose of the call is to discuss the unaudited financial results for the quarter and nine months ended December 31, 2025. This is a standard procedural update following the conclusion of the third quarter of the financial year. The call will provide institutional investors and analysts an opportunity to interact with the management regarding the company's performance.

Earnings call scheduled for January 30, 2026, at 4:30 PM IST
Discussion to focus on Q3 and 9M results for the period ending December 31, 2025
Meeting format is a Group Conference Call for analysts and institutional investors
Details and invitation are available on the company's official website and exchange filings

💡 Investors should mark the date to listen for management commentary on margin expansion and debt levels. No immediate action is required as this is a routine scheduling announcement.

Strides Pharma Submits SEBI Compliance Certificate for Quarter Ended Dec 31, 2025

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 14 Jan 2026, 03:03 PM

Strides Pharma Science Limited has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by KFin Technologies Limited, confirms that all security dematerialization and rematerialization requests for the quarter ended December 31, 2025, have been processed. These details have been officially reported to both the National Stock Exchange (NSE) and BSE Limited. This is a standard procedural filing required to maintain regulatory transparency regarding the company's share capital.

Compliance certificate submitted for the quarter ended December 31, 2025
Issued by Registrar and Share Transfer Agent (RTA), KFin Technologies Limited
Confirms reporting of dematerialized and rematerialized securities to NSE and BSE
Mandatory filing under Regulation 74(5) of SEBI (Depositories and Participants) Regulations

💡 This is a routine administrative filing with no impact on the company's fundamentals or stock valuation; no action is required from investors.

Strides Pharma's US Facility Receives 4 Procedural Observations from USFDA

🟡 NEUTRAL ⭐ 6/10

REGULATORY 📅 24 Dec 2025, 06:28 PM

Strides Pharma Science Limited's US-based subsidiary, Strides Pharma Inc., underwent a routine USFDA inspection at its Chestnut Ridge facility in New York from December 17 to December 23, 2025. The inspection concluded with the issuance of Form 483 containing four observations. Management has characterized these observations as procedural in nature and does not expect any disruption to the supply of commercial products. The company is currently preparing a comprehensive response to address the USFDA's concerns within the required timeframe.

Routine USFDA cGMP inspection conducted at Chestnut Ridge, New York facility from Dec 17-23, 2025
Form 483 issued with 4 procedural observations at the conclusion of the inspection
Company confirms no anticipated impact on the supply of its commercial products
Strides Pharma Inc. to submit a comprehensive response to the USFDA within the stipulated time

💡 Investors should monitor for the final EIR (Establishment Inspection Report) from the USFDA to ensure the observations are closed without escalation. As commercial supply remains unaffected, no immediate portfolio changes are necessary.

Strides Pharma to Close Trading Window from Jan 1, 2026 for Q3 FY26 Results

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 22 Dec 2025, 05:50 PM

Strides Pharma Science Limited has announced the closure of its trading window starting January 1, 2026, in compliance with SEBI insider trading regulations. This closure is ahead of the declaration of financial results for the quarter and nine months ending December 31, 2025. The window will remain closed for all designated persons until 48 hours after the results are made public. The specific date for the board meeting to approve these results will be notified at a later date.

Trading window closure effective from January 1, 2026.
Closure pertains to financial results for the quarter ended December 31, 2025.
Window to reopen 48 hours after the official declaration of financial results.
Compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

💡 This is a routine regulatory announcement with no direct impact on stock fundamentals. Investors should wait for the announcement of the board meeting date to assess the company's quarterly performance.

View All STAR Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Overall revenue grew 4.6% YoY in Q2 FY26 to INR 12,208m. US market grew 2% YoY to $73m. Growth Markets (Africa, LATAM, MENA, APAC) saw revenue of INR 1,468m ($17m) in Q2 FY26, with FY25 growth at 24.2% YoY. Access Market revenue stood at INR 609m ($7m) for Q2 FY26. Other Regulated Markets (ORM) revenue is currently in the $44m range per quarter.

Geographic Revenue Split

US Market contributes approximately 50% of revenue (INR 2,445 Cr out of INR 4,571.86 Cr in FY25). Other Regulated Markets contributed INR 1,358 Cr (approx. 30%) in FY25. Growth Markets and Access Markets make up the remaining 20%.

Profitability Margins

Gross margins improved to 57.8% in Q2 FY26 (up 500bps YoY) and reached 59% for H1 FY26. This expansion is structural, driven by a calibrated approach to onboarding high-margin business and avoiding 'loss leaders'. Operational PAT grew 84.3% YoY to INR 1,403m in Q2 FY26, reflecting a 20x multiplier effect from revenue growth due to operating leverage.

EBITDA Margin

EBITDA margin stood at 19.0% in Q2 FY26, a 320bps YoY improvement. Absolute EBITDA grew 25.4% YoY to INR 2,316m. For H1 FY26, EBITDA was INR 450 Cr with a 20% growth rate, driven by steady operating costs at 39% of sales.

Capital Expenditure

Maintenance capex is focused on factory upkeep rather than R&D. While specific total INR Cr for future expansion is not explicitly totaled, the company is 'sweating out' existing assets to create operating leverage from under-recoveries at plants.

Credit Rating & Borrowing

The company has a moderate credit profile with improving debt servicing capacity. Net finance costs for H1 FY26 were INR 61 Cr, significantly lower than INR 105 Cr in H1 FY25. Rating sensitivity requires maintaining net total debt to PBILDT below 1.6x.

⚙️ Operational Drivers

Raw Materials

Not disclosed in available documents; however, variable costs and product mix are cited as the primary drivers of the 59% gross margin.

Key Suppliers

Not disclosed in available documents; company maintains a 'reputed clientele' and 'low product concentration risks'.

Capacity Expansion

Current focus is on addressing 'under recoveries' across existing plants to drive incremental revenue without new operating costs. The company aims to scale US revenue to $400m (~INR 3,500 Cr) within three years using existing infrastructure.

Raw Material Costs

Gross margins of 57.8% imply raw material and direct production costs are approximately 42.2% of revenue. The company follows a 'calibrated approach' to product selection to maintain these margins.

Manufacturing Efficiency

Operating leverage is being achieved by increasing revenue (4.6% growth) while keeping operating costs steady at 39% of sales, resulting in a 5x-6x multiplier effect on EBITDA growth.

📈 Strategic Growth

Expected Growth Rate

10%

Growth Strategy

Growth will be achieved through a target of 60 new product launches in the US over 3 years, strategic partnerships with at least three pharmaceutical companies in the Middle East, and expanding the channel partner network in Growth Markets (Africa, LATAM, APAC).

Products & Services

Pharmaceutical products including medicines for the US market, Other Regulated Markets, and Growth Markets (Africa/LATAM), specifically focusing on niche molecules where they hold leadership positions.

Brand Portfolio

Strides Pharma Science Limited.

New Products/Services

Initiated a wave of regulatory filings in new territories; US product launch run rate is currently being monitored to meet the 60-product 3-year goal.

Market Expansion

Targeting the Middle East through strategic partnerships and expanding in Africa via new product launches which led Q2 growth.

Market Share & Ranking

The company claims 'leadership positions' in the specific niche products they sell.

Strategic Alliances

In discussions with at least three leading pharmaceutical companies in the Middle East to forge strategic partnerships.

🌍 External Factors

Industry Trends

The industry is seeing a shift toward 'profitability over volume'. Strides is positioning itself by exiting low-margin products and focusing on 'operating leverage' where small revenue increases (4.6%) lead to massive PAT increases (84%).

Competitive Landscape

Faces rising competitive intensity in the US market, particularly on certain molecules, which the company counters by focusing on margin thresholds.

Competitive Moat

Moat is built on 'accredited manufacturing facilities', a 'calibrated approach' to niche product selection, and a track record of turning around businesses. These are sustainable due to high regulatory barriers to entry for manufacturing.

Macro Economic Sensitivity

Sensitive to donor funding cycles for the Access Market and regulatory timelines in international territories.

Geopolitical Risks

Operations in Africa and MENA regions introduce geographic-specific regulatory and stabilization risks over the next two years.

⚖️ Regulatory & Governance

Industry Regulations

Operations are subject to 'inherent regulatory risks' and 'extended regulatory timelines' in new territories which can cause quarterly variability for up to two years.

Taxation Policy Impact

Effective Tax Rate (ETR) for Q2 and H1 FY26 was approximately 15%; expected to be in the range of 15% to 20% for the full year.

⚠️ Risk Analysis

Key Uncertainties

The 'high pledge of promoter's shares' is a key weakness and a monitorable for credit ratings. Regulatory delays in new markets could impact the 3-year $400m US revenue target.